FDA is accepting applications for its Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01). This program is administered by the FDA’s Office of Orphan Products Development.
The Supreme Court last week upended one of the underpinnings of administrative law by weakening the authority of federal health agencies to rely on technical expertise as they regulate medical products, issue coverage decisions, and respond to public health crises.
